Journal of Diagnostics Concepts & Practice >

2022 , Vol. 21 >Issue 03: 408 - 414

DOI: https://doi.org/10.16150/j.1671-2870.2022.03.021

Review article

Study on advances in the association between autoantibodies and clinical phenotypes in idiopathic inflammatory myopathy

Expand
  • Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025 China

Received date: 2022-01-20

  Online published: 2022-08-17

Fold

Abstract

Myositis specific autoantibodies(MSA) are important for the diagnosis and classification of idiopathic inflammatory myopathy (IIM). It reveales that there is a close relationship between various types of MSA and unique clinical manifestations as well as pathological phenotypes. The titers of some autoantibodies are also correlated with the disease activity score and prognosis. Therefore, detection of MSA is helpful to the identification of the disease subtypes, personalized treatment selection and the judgement of prognosis in clinical practice. In future, more in-depth researches on MSA are needed to furtherly explore the pathogenic mechanism of the disease.

Key words： Idiopathic inflammatory myopathy; Autoantibodies; Dermatomyositis; Polymyositis

Cite this article

ZHANG Hao, CHI Huihui, SU Yutong, YANG Chengde . Study on advances in the association between autoantibodies and clinical phenotypes in idiopathic inflammatory myopathy[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(03) : 408 -414 . DOI: 10.16150/j.1671-2870.2022.03.021

References

[1] Witt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome[J]. Clin Pulm Med, 2016, 23(5):218-226.
[2] Zhang Y, Ge Y, Yang H, et al. Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome[J]. Clin Rheumatol, 2020, 39(8):2417-2424.
[3] Ueki M, Kobayashi I, Takezaki S, et al. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies[J]. Mod Rheumatol, 2019, 29(2):351-356.
[4] Gupta L, Naveen R, Gaur P, et al. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis[J]. Semin Arthritis Rheum, 2021, 51(1):113-120.
[5] Xu Q, Li QX, Bi FF, et al. The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies[J]. Clin Rheumatol, 2021, 40(2):613-624.
[6] Mescam-Mancini L, Allenbach Y, Hervier B, et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis[J]. Brain, 2015, 138(Pt 9):2485-2492.
[7] Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies[J]. Rheumatology (Oxford), 2017, 56(6):999-1007.
[8] Yang Y, Liu Y, Huang L, et al. Clinical Features and cytokine profile in myositis patients with anti-EJ autoantibodies detected by a novel immunoprecipitation assay[J]. Biomed Res Int, 2019, 2019:1856180.
[9] Ge Y, Li S, Li S, et al. Interstitial lung disease is a major characteristic of anti-KS associated ant-synthetase syndrome[J]. Ther Adv Chronic Dis, 2020, 11:2040622320 968417.
[10] Zhan X, Yan W, Wang Y, et al. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China[J]. BMC Pulm Med, 2021, 21(1):57.
[11] Bergua C, Chiavelli H, Allenbach Y, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy[J]. Ann Rheum Dis, 2019, 78(1):131-139.
[12] Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients[J]. J Autoimmun, 2019, 101:48-55.
[13] Benveniste O, Drouot L, Jouen F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myo-pathy[J]. Arthritis Rheum, 2011, 63(7):1961-1971.
[14] Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients[J]. Orphanet J Rare Dis, 2015, 10:61.
[15] Liang WC, Uruha A, Suzuki S, et al. Pediatric necroti-zing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies[J]. Rheumatology (Oxford), 2017, 56(2):287-293.
[16] Tiniakou E, Pinal-Fernandez I, Lloyd TE, et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy[J]. Rheumatology (Oxford), 2017, 56(5):787-794.
[17] Tanboon J, Inoue M, Hirakawa S, et al. Pathologic features of anti-Mi-2 dermatomyositis[J]. Neurology, 2021, 96(3):e448-e459.
[18] Liang L, Zhang YM, Chen H, et al. Anti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis[J]. Eur J Dermatol, 2020, 32(5):103-112.
[19] Ge Y, Lu X, Shu X, et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts[J]. Sci Rep, 2017, 7(1):188.
[20] Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum[J]. Arthritis Care Res (Hoboken), 2013, 65(8):1307-1315.
[21] Chen Z, Hu W, Wang Y, et al. Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis[J]. Clin Rheumatol, 2015, 34(9):1627-1631.
[22] Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases[J]. Neurology, 2020, 95(1):e70-e78.
[23] Yamaguchi K, Yamaguchi A, Onuki Y, et al. Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age[J]. Mod Rheumatol, 2021, 31(1):177-185.
[24] Mamyrova G, Kishi T, Shi M, et al. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America[J]. Rheumatology (Oxford), 2021, 60(4):1839-1849.
[25] Bermudez J, Heim X, Bertin D, et al. Lung involvement associated with anti-NXP2 autoantibodies in inflammatory myopathies: a French monocenter series[J]. Expert Rev Respir Med, 2020, 14(8):845-850.
[26] Sag E, Demir S, Bilginer Y, et al. Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis[J]. Semin Arthritis Rheum, 2021, 51(1):95-100.
[27] Sung YK, Jung SY, Kim H, et al. Temporal relationship between idiopathic inflammatory myopathies and malignancies and its mortality: a nationwide population-based study[J]. Clin Rheumatol, 2020, 39(11):3409-3416.
[28] Best M, Molinari N, Chasset F, et al. Use of anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis[J]. Acta Derm Venereol, 2019, 99(3):256-262.
[29] Venalis P, Selickaja S, Lundberg K, et al. Association of anti-transcription intermediary factor 1γ antibodies with paraneoplastic rheumatic syndromes other than dermatomyositis[J]. Arthritis Care Res (Hoboken), 2018, 70(4):648-651.
[30] Oldroyd A, Sergeant JC, New P, et al. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis[J]. Rheumatology (Oxford), 2019, 58(4):650-655.
[31] Wong VT, So H, Lam TT, et al. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies[J]. Acta Neurol Scand, 2021, 143(2):131-139.
[32] Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy[J]. Ann Rheum Dis, 2012, 71(5):710-713.
[33] Betteridge Z, Gunawardena H, Chinoy H, et al. Clinical associations of anti-p140 autoantibodies in adult myositis[J]. Ann Rheum Dis, 2010, 69(Suppl3):127.
[34] Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy[J]. Neurol Neuroimmunol Neuroinflamm, 2016, 3(6):e290.
[35] Monseau G, Landon-Cardinal O, Stenzel W, et al. Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: a classic skin rash with a necrotizing myositis and high risk of malignancy[J]. J Am Acad Dermatol, 2020, 83(6):1759-1763.
[36] Petri MH, Satoh M, Martin-Marquez BT, et al. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara[J]. Arthritis Res Ther, 2013, 15(2):R48.
[37] Yang H, Peng Q, Yin L, et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study[J]. Arthritis Res Ther, 2017, 19(1):259.
[38] Felice KJ, Whitaker CH, Wu Q, et al. Sensitivity and clinical utility of the anti-cytosolic 5′-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: Report of 40 patients from a single neuromuscular center[J]. Neuromuscul Disord, 2018, 28(8):660-664.
[39] Lucchini M, Maggi L, Pegoraro E, et al. Anti-cN1A antibodies are associated with more severe dysphagia in sporadic inclusion body myositis[J]. Cells, 2021, 10(5):1146.
[40] Lilleker JB, Rietveld A, Pye SR, et al. Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characte-ristics in inclusion body myositis[J]. Ann Rheum Dis, 2017, 76(5):862-868.
Options
Outlines

/

〈 〉